Clinical trials: Non Small Cell
Carcinoma, Non-Small-Cell Lung
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NEXUS (NCT00449033)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Gemcitabine, Cisplatin
- Where
- 122 sites in Austria, Belgium and 16 more
- Volunteers
- 904 people
- Sponsor
- Bayer
Non-Squamous Non-Small Cell Lung Cancer
A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This open label, 2-part study will evaluate the safety and efficacy of RO5083945 in combination with standard chemotherapy in patients with advanced or recurrent non-small cell lung cancer who have not received prior…
- Trial name
- NCT01185847
- Testing
- RO5083945, cisplatin, gemcitabine
- Where
- 32 sites in Belgium, France and 5 more
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Cancer, Non-Small Cell Lung Cancer
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of XL147 in combination with paclitaxel and carboplatin in adults with solid tumors. XL147 is a new chemical entity that inhibits PI3 Kinase.
- Conditions
- Cancer, Non-Small Cell Lung Cancer, Endometrial Carcinoma, Ovarian Carcinoma
- Trial name
- NCT00756847
- Testing
- XL147 (SAR245408),, paclitaxel, carboplatin
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is a randomized, active control, open-label, phase 2 trial. Erlotinib-treated NSCLC patients will be screened for Globo H, and only Globo H+ (H score ≥ 100) subjects are eligible for the study.
- Trial name
- EGFR (NCT05442060)
- Testing
- 30 μg OBI-833/100 μg OBI-821, Erlotinib (150 mg daily)
- Where
- 7 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- OBI Pharma, Inc
Non-small Cell Lung Cancer
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following…
- Trial name
- COMPEL (NCT04765059)
- Testing
- Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
- Where
- 40 sites in United States, China and 4 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Leukemia, Lymphoma
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00436618
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 277 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
This is a multicenter, two part (Part A and Part B) clinical study of CMP-001 administered intratumorally (IT) and subcutaneously (SC) in combination with atezolizumab with or without radiation therapy in participants with NSCLC.
- Trial name
- NCT03438318
- Testing
- CMP-001, Atezolizumab, Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Regeneron Pharmaceuticals
Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC)
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
The goal of this clinical trial is to assess the efficacy of ivonescimab monotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations who have received prior targeted therapies and…
- Conditions
- Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell), Lung Cancer - Non Small Cell
- Trial name
- NCT07405190
- Testing
- Ivonescimab, carboplatin, pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Massachusetts General Hospital
Non-small Cell Lung Cancer
To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)
To evaluate the safety and tolerability of carbognilumab combined with chemotherapy as first-line treatment in patients with KeAP1-mutated advanced or postoperative recurrent non-small cell lung cancer.
- Trial name
- NCT06341660
- Testing
- cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Non Small Cell Lung Cancer, Immunotherapy
Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC
This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date.
- Conditions
- Non Small Cell Lung Cancer, Immunotherapy, Chemotherapy, Tumour, Residual
- Trial name
- NCT05637580
- Testing
- Timing of drug administration
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Guangdong Provincial People's Hospital
Carcinoma, Non-Small-Cell Lung
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
The purpose of this study is to describe the clinical and health-related outcomes of amivantamab-containing regimens for the treatment of common epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC…
- Trial name
- LEPIDOPTERA (NCT07230691)
- Where
- 86 sites in Austria, Belgium and 6 more
- Volunteers
- 380 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small-Cell Lung Cancer, Carcinoma
Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection
Despite improved staging and operative techniques, the rate of incomplete resection (R1) of NSCLC has remained significant over the last decades.
- Trial name
- LINNEARRE-I (NCT02433574)
- Testing
- Neoadjuvant Stereotactic body radiation (SBRT)
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Juravinski Cancer Center
Carcinoma, Non-Small-Cell Lung
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with…
- Trial name
- NCT06875310
- Testing
- Adagrasib, Pembrolizumab, Carboplatin
- Where
- 317 sites in United States, Argentina and 33 more
- Volunteers
- 630 people
- Sponsor
- Mirati Therapeutics Inc.
Non Small Cell Lung Cancer
A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC
The purpose of this study is to determine the feasibility and evaluate the safety of delivering chemotherapy, the usual approach to non-small cell lung cancer, in combination with Sintilimab (PD-1 antibody), followed by adjuvant…
- Trial name
- NCT04840290
- Testing
- Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Carcinoma, Non-Small-Cell Lung
Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer
The primary objective was to determine the safety, tolerability and maximum tolerate dose (MTD) of BIBF 1120 in combination with pemetrexed.
- Trial name
- NCT02182102
- Testing
- BIBF 1120, Pemetrexed
- Volunteers
- 26 people
- Sponsor
- Boehringer Ingelheim
Immunotherapy, Intensity Modulated Radiation Therapy
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC.
- Conditions
- Immunotherapy, Intensity Modulated Radiation Therapy, Radiotherapy, NSCLC
- Trial name
- NCT05909137
- Testing
- IMRT+adjuvant immunotherapy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xinqiao Hospital of Chongqing
Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage 0
Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety.
Effects of Qigong on symptom clusters of dyspnea, fatigue, and anxiety in Vietnamese lung cancer patients: A randomized control trial
- Conditions
- Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage 0, Lung Cancer, Nonsmall Cell, Stage I, Lung Cancer Non-Small Cell Stage II
- Trial name
- NCT02977845
- Testing
- Qigong
- Where
- Hong Kong
- Volunteers
- 162 people
- Sponsor
- Nam Dinh University of Nursing
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Lung Cancer
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer
Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer.
- Trial name
- NCT00002537
- Testing
- topotecan hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Any Advanced Solid Tumors, Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the…
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04332653
- Testing
- NT-I7, pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NeoImmuneTech